News Headlines Article

Two new cholesterol drugs raise questions of cost and access
Modern Healthcare

FDA advisory panels this week recommended approval of two drugs that may significantly lower cholesterol. But experts warn the potential high cost for these blockbuster drugs could limit their access and once again raise concerns about skyrocketing prescription costs.

An advisory committee Wednesday voted 11-4 to recommend approval for drug maker Amgen’s injectable drug Repatha. It treats high-risk patients. On Tuesday, an advisory panel voted 13-3 to recommend approval for Praluent, an injectable medication produced by Sanofi and Regeneron Pharmaceuticals.